# EDGAR Filing Document

**Accession Number:** 0001253581
**File Stem:** 0001193125-26-134281
**Filing Date:** 2026-3
**Character Count:** 5755
**Document Hash:** 3cfb56e4a530f21c602b47e40331f3f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-134281.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001193125-26-134281

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** HAIGHT NELSON M
- **CENTRAL INDEX KEY:** 0001253581

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41440
- **FILM NUMBER:** 26821065

**MAIL ADDRESS:**
- **STREET 1:** 110 B JACKSON BLVD
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77006
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Virax Biolabs Group Ltd
- **CENTRAL INDEX KEY:** 0001885827
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**BUSINESS ADDRESS:**
- **STREET 1:** BIOCITY GLASGOW
- **STREET 2:** BO'NESS ROAD, NEWHOUSE
- **CITY:** LANARKSHIRE
- **STATE:** X0
- **ZIP:** ML1 5UH
- **BUSINESS PHONE:** 44 020 7788 7414

**MAIL ADDRESS:**
- **STREET 1:** BIOCITY GLASGOW
- **STREET 2:** BO'NESS ROAD, NEWHOUSE
- **CITY:** LANARKSHIRE
- **STATE:** X0
- **ZIP:** ML1 5UH

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virax Biolabs (Cayman) Ltd
- **DATE OF NAME CHANGE:** 20210930

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>HAIGHT NELSON M<br><sub>(Last) (First) (Middle)</sub><br>BIOCITY GLASGOW BO'NESS ROAD<br>NEWHOUSE LANARKSHIRE<br><sub>(Street)</sub><br>MOTHERWELL LANARKSHIRE, UNITED KINGDOM ML1 5UH<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Virax Biolabs Group Ltd [ VRAX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Options (right to buy) | <sup>(1)</sup> | 2032-11-17 | Ordinary Shares | 2000 | $15.40 | D |  |
| Stock Options (right to buy) | <sup>(2)</sup> | 2033-04-18 | Ordinary Shares | 10000 | $6.00 | D |  |
| Stock Options (right to buy) | <sup>(3)</sup> | 2034-04-18 | Ordinary Shares | 10000 | $0.68 | D |  |
| Stock Options (right to buy) | <sup>(4)</sup> | 2035-04-08 | Ordinary Shares | 10000 | $0.88 | D |  |

---

### Footnotes:

(1) On November 17, 2022, the Company granted 2,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on November 17 of each of 2023 and 2024. The vested portions of such options will become exercisable upon vesting.

(2) On April 18, 2023, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on April 18 of each of 2024 and 2025. The vested portions of such options will become exercisable upon vesting.

(3) On April 18, 2024, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.

(4) On April 8, 2025, the Company granted 10,000 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

**Signature:** /s/ Nelson Haight  
**Date:** 2026-03-31

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**